Related references
Note: Only part of the references are listed.Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody
Zhongyu Zhu et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2
Thomas A. Bowden et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
Host cell recognition by the henipaviruses: Crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3
Kai Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
Zhongyu Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Neutralization assays for differential henipavirus serology using Bio-Plex Protein Array Systems
Katharine N. Bossart et al.
JOURNAL OF VIROLOGICAL METHODS (2007)
Structural definition of a conserved neutralization epitope on HIV-1 gp120
Tongqing Zhou et al.
NATURE (2007)
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R
William C. Hwang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants
Jan ter Meulen et al.
PLOS MEDICINE (2006)
Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody
Ponraj Prabakaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Antibody prophylaxis and therapy against Nipah virus infection in hamsters
V Guillaume et al.
JOURNAL OF VIROLOGY (2006)
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies
ZY Zhu et al.
JOURNAL OF VIROLOGY (2006)
Hendra and Nipah viruses: different and dangerous
BT Eaton et al.
NATURE REVIEWS MICROBIOLOGY (2006)
Bats are natural reservoirs of SARS-like coronaviruses
WD Li et al.
SCIENCE (2005)
Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
SKP Lau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
F Li et al.
SCIENCE (2005)
Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain
CE Yi et al.
JOURNAL OF VIROLOGY (2005)
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus
MI Bonaparte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A human SARS-CoV neutralizing antibody against epitope on S2 protein
JZ Duan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization
H Wu et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus
KN Bossart et al.
JOURNAL OF VIROLOGY (2005)
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants
JH Sui et al.
JOURNAL OF VIROLOGY (2005)
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies
YX He et al.
JOURNAL OF IMMUNOLOGY (2005)
In vivo selection of respiratory syncytial viruses resistant to palivizumab
XD Zhao et al.
JOURNAL OF VIROLOGY (2005)
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: Importance for designing SARS vaccines
YX He et al.
VIROLOGY (2005)
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region
ZW Chen et al.
JOURNAL OF VIROLOGY (2005)
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice
TC Greenough et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus
EN van den Brink et al.
JOURNAL OF VIROLOGY (2005)
Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses
ZY Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice
D Qu et al.
VACCINE (2005)
The SARS Coronavirus S Glycoprotein Receptor Binding Domain: Fine Mapping and Functional Characterization
Samitabh Chakraborti et al.
VIROLOGY JOURNAL (2005)
Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus
MJ Gubbins et al.
MOLECULAR IMMUNOLOGY (2005)
Severe acute respiratory syndrome coronavirus infection of Golden Syrian hamsters
A Roberts et al.
JOURNAL OF VIROLOGY (2005)
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice
H Bisht et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
ZY Yang et al.
NATURE (2004)
Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice
K Subbarao et al.
JOURNAL OF VIROLOGY (2004)
Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments
FY Zeng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
JH Sui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Susceptibility of pigs and chickens to SARS coronavirus
HM Weingartl et al.
EMERGING INFECTIOUS DISEASES (2004)
Virus entry: Molecular mechanisms and biomedical applications
DS Dimitrov
NATURE REVIEWS MICROBIOLOGY (2004)
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2
SK Wong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine
P Hai et al.
JOURNAL OF GENERAL VIROLOGY (2004)
Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection
YC Nie et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: Implication for developing SARS diagnostics and vaccines
YX He et al.
JOURNAL OF IMMUNOLOGY (2004)
Immunogenicity of SARS inactivated vaccine in BALB/c mice
S Xiong et al.
IMMUNOLOGY LETTERS (2004)
Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients
YL Shi et al.
JOURNAL OF CLINICAL VIROLOGY (2004)
Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
JD Berry et al.
JOURNAL OF VIROLOGICAL METHODS (2004)
Passive antibody therapy for infectious diseases
A Casadevall et al.
NATURE REVIEWS MICROBIOLOGY (2004)
Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein
DP Han et al.
VIROLOGY (2004)
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus
E Traggiai et al.
NATURE MEDICINE (2004)
Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection
X Sáez-Llorens et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry
YX He et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys
J McAuliffe et al.
VIROLOGY (2004)
An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies
T Zhou et al.
JOURNAL OF VIROLOGY (2004)
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies
H Zhang et al.
JOURNAL OF VIROLOGY (2004)
Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein
YX Yao et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus
PR Hsueh et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
SARS corona virus peptides recognized by antibodies in the sera of convalescent cases
JP Guo et al.
VIROLOGY (2004)
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
UJ Buchholz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
A Bukreyev et al.
LANCET (2004)
Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
J ter Meulen et al.
LANCET (2004)
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine
YX He et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets
H Weingartl et al.
JOURNAL OF VIROLOGY (2004)
Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice
L Tang et al.
DNA AND CELL BIOLOGY (2004)
Nipah virus: Vaccination and passive protection studies in a hamster model
V Guillaume et al.
JOURNAL OF VIROLOGY (2004)
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?
J Bayry et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients
H Hofmann et al.
JOURNAL OF VIROLOGY (2004)
The SARS-CoV S glycoprotein
X Xiao et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice
N Takasuka et al.
INTERNATIONAL IMMUNOLOGY (2004)
The SARS-CoV S glycoprotein: expression and functional characterization
XD Xiao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Effects of a SARS-associated coronavirus vaccine in monkeys
WT Gao et al.
LANCET (2003)
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
WH Li et al.
NATURE (2003)
A novel coronavirus associated with severe acute respiratory syndrome
TG Ksiazek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
C Drosten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome
JR Kerr et al.
CLINICAL INFECTIOUS DISEASES (2003)
Coronavirus as a possible cause of severe acute respiratory syndrome
JSM Peiris et al.
LANCET (2003)
A passive immunotherapy, PEHRG214, in patients infected with human immunodeficiency virus:: a phase I study
BJ Dezube et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda
LA Guay et al.
AIDS (2002)
Introduction to current focus on Hendra and Nipah viruses
BT Eaton
MICROBES AND INFECTION (2001)
Antibodies for the prevention and treatment of viral diseases
LA Sawyer
ANTIVIRAL RESEARCH (2000)
Nipah virus: A recently emergent deadly paramyxovirus
KB Chua et al.
SCIENCE (2000)
Clinical features of nipah virus encephalitis among pig farmers in Malaysia.
KJ Goh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Preventing infectious disease with passive immunization
L Zeitlin et al.
MICROBES AND INFECTION (2000)
Risk factors for Nipah virus infection among abattoir workers in Singapore
MHL Chew et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Share Paper
